Last reviewed · How we verify
AST-OPC1
AST-OPC1 is a human oligodendrocyte progenitor cell therapy that promotes myelination and repair in spinal cord injuries.
AST-OPC1 is a human oligodendrocyte progenitor cell therapy that promotes myelination and repair in spinal cord injuries. Used for Acute spinal cord injury.
At a glance
| Generic name | AST-OPC1 |
|---|---|
| Sponsor | Lineage Cell Therapeutics, Inc. |
| Drug class | cell therapy |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | Phase 1 |
Mechanism of action
AST-OPC1 is designed to differentiate into oligodendrocytes, which produce myelin to insulate nerve fibers, thereby improving neural function and recovery after spinal cord injury.
Approved indications
- Acute spinal cord injury
Common side effects
Key clinical trials
- LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1
- Dose Escalation Study of AST-OPC1 in Spinal Cord Injury (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AST-OPC1 CI brief — competitive landscape report
- AST-OPC1 updates RSS · CI watch RSS
- Lineage Cell Therapeutics, Inc. portfolio CI